News for Atea Pharmaceuticals, Inc. (AVIR)

Enters into Agreement with Bradley L. Radoff and Michael Torok BOSTON, April 17, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. ( AVIR) (”œAtea” or

**media[597920]**

Morgan Stanley has revised its price target for Atea Pharmaceuticals (AVIR), reducing it slightly from $6.20 to $6. The financial services firm continues to mai

Atea Pharmaceuticals (AVIR) doses the first patient in its Phase 3 trial C-BEYOND for hepatitis C treatment. The trial evaluates a combination regimen o

Canada-based Venus Concept Inc (VERO) is up over 310 percent in Wednesday's pre-market trading. The following are some of the other stocks making big moves in Wednesday's pre-market trading.

**media[582121]**

**media[577694]**

No Shareholder Action is Required at this TimeBOSTON, March 21, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company) a clinica

**media[573358]**

We came across a bullish thesis on Atea Pharmaceuticals, Inc. (AVIR) on Substack by Turtles Research. In this article, we will summarize the bulls’ thesis on AVIR. Atea Pharmaceuticals, Inc.

BOSTON, March 19, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. ( AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the dis

Cash and Marketable Securities: $454.7 million as of December 31, 2024.Cash Runway: Expected to extend into 2028.R&D Expenses: Increased year over year in 2024

The following slide deck was published by Atea Pharmaceuticals, Inc.

Discover Atea Pharmaceuticals' Q4 results: GAAP EPS of -$0.40, missing estimates by $0.03, with shares slightly improving at +0.33%.

**media[552055]**

BOSTON, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. ( AVIR) (”œAtea”), a clinical-stage biopharmaceutical company engaged in the discovery

**media[548306]**

BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. ( AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the disc

EcoR1 Capital, LLC (Trades, Portfolio), a prominent investment firm, recently made a strategic decision to reduce its holdings in Atea Pharmaceuticals Inc (AVIR